Matthieu Ludovic Jeanty

Title: Matthieu Ludovic Jeanty: Innovator in Pharmaceutical Chemistry

Introduction

Matthieu Ludovic Jeanty is a notable inventor based in Louviers, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as inhibitors for various medical applications. With a total of six patents to his name, Jeanty has established himself as a key figure in innovative drug development.

Latest Patents

Jeanty's latest patents include the development of substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors. These compounds are designed to be useful in treating conditions related to ROS1, a gene that can play a role in cancer. Another significant patent involves substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives, which also serve as ROS1 inhibitors. The inventions not only describe the compounds but also outline processes for their preparation and their use in pharmaceutical compositions.

Career Highlights

Throughout his career, Matthieu Jeanty has worked with prominent companies in the pharmaceutical industry, including Astex Therapeutics Limited and Janssen Pharmaceutica. His work has focused on creating innovative solutions that address critical health challenges through advanced chemical compounds.

Collaborations

Jeanty has collaborated with esteemed colleagues such as Michel Obringer and Patrick Rene Angibaud. These partnerships have contributed to the successful development of his patented inventions and have enhanced the impact of his work in the pharmaceutical field.

Conclusion

Matthieu Ludovic Jeanty is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of important compounds for medical use. His contributions continue to influence the industry and pave the way for future innovations.